Loading...
Market
Competitor response to Blenrep trial results by end of 2024
5
Resolution / Starting Odds
Launch new competing drug • 33%
Enhance marketing of existing drugs • 33%
No significant response • 34%
Competitor press releases, pharmaceutical news outlets
Story
GSK's Blenrep Shows 50% Risk Reduction in Multiple Myeloma Trial
Jun 2, 2024, 12:25 PM
At the ASCO24 conference, GlaxoSmithKline (GSK) presented promising results for its blood cancer drug, Blenrep, in the Phase 3 DREAMM-8 trial. The trial, which involved 302 patients, showed that Blenrep, when combined with pomalidomide and dexamethasone, significantly reduced the risk of disease progression or death by nearly 50% in patients with relapsed or refractory multiple myeloma. This combination resulted in a 20 percentage point higher one-year progression-free survival compared to a regimen including bortezomib. These findings could pave the way for Blenrep's return to the market after it was previously withdrawn following a trial failure.
View original story
Similar markets
Launch of similar drug • 33%
Acquisition or partnership announcements • 33%
No significant response • 34%
Novo Nordisk launches competitive drug • 30%
Pfizer accelerates similar drug development • 30%
No significant competitor response • 40%
No competitors respond • 25%
1-2 competitors respond • 25%
3-5 competitors respond • 25%
More than 5 competitors respond • 25%
No competitive drugs launched • 25%
1-2 competitive drugs launched • 25%
3-5 competitive drugs launched • 25%
More than 5 competitive drugs launched • 25%
Increased investment in existing Alzheimer's drugs • 33%
Development of new APOE4-specific treatments • 33%
No significant change in investment • 33%
